The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $57.59 in the prior trading day, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $58.09, up 0.87%. In other words, the price has increased by $0.87 from its previous closing price. On the day, 1.35 million shares were traded. CRSP stock price reached its highest trading level at $59.245 during the session, while it also had its lowest trading level at $56.61.
Ratios:
Our goal is to gain a better understanding of CRSP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.22 and its Current Ratio is at 16.22. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In the most recent recommendation for this company, JP Morgan on September 18, 2025, initiated with a Overweight rating and assigned the stock a target price of $70. On February 14, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line and also upped its target price recommendation from $60 to $99. TD Cowen Upgraded its Sell to Hold on February 12, 2025, while the target price for the stock was maintained at $35.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 17 ’25 when Kulkarni Samarth sold 50,895 shares for $67.91 per share. The transaction valued at 3,456,279 led to the insider holds 254,201 shares of the business.
Kulkarni Samarth sold 4,242 shares of CRSP for $282,517 on Oct 14 ’25. The Chief Executive Officer now owns 205,096 shares after completing the transaction at $66.60 per share. On Oct 14 ’25, another insider, KASINGER JAMES R., who serves as the General Counsel and Secretary of the company, sold 1,076 shares for $66.60 each. As a result, the insider received 71,662 and left with 83,402 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5535990272 and an Enterprise Value of 3831304448. For the stock, the TTM Price-to-Sale (P/S) ratio is 144.39 while its Price-to-Book (P/B) ratio in mrq is 2.85. Its current Enterprise Value per Revenue stands at 99.938 whereas that against EBITDA is -8.338.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.69, which has changed by 0.32686162 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $78.48, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is -4.66%, while the 200-Day Moving Average is calculated to be 14.51%.
Shares Statistics:
The stock has traded on average 2.55M shares per day over the past 3-months and 1822920 shares per day over the last 10 days, according to various share statistics. A total of 93.87M shares are outstanding, with a floating share count of 91.32M. Insiders hold about 4.17% of the company’s shares, while institutions hold 71.44% stake in the company. Shares short for CRSP as of 1764288000 were 22431985 with a Short Ratio of 8.80, compared to 1761868800 on 21033230. Therefore, it implies a Short% of Shares Outstanding of 22431985 and a Short% of Float of 26.419999999999998.
Earnings Estimates
As of right now, 17.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.87 and low estimates of -$1.25.
Analysts are recommending an EPS of between -$4.97 and -$6.86 for the fiscal current year, implying an average EPS of -$6.2. EPS for the following year is -$4.46, with 19.0 analysts recommending between -$2.0 and -$6.22.
Revenue Estimates
A total of 23 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $27.6M, while the lowest revenue estimate was $2.6M, resulting in an average revenue estimate of $6.12M. In the same quarter a year ago, actual revenue was $37.31M
